LGT Capital Partners LTD. boosted its position in shares of Celgene Co. (NASDAQ:CELG) by 24.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 665,466 shares of the biopharmaceutical company’s stock after purchasing an additional 131,880 shares during the quarter. Celgene comprises about 3.5% of LGT Capital Partners LTD.’s holdings, making the stock its 5th biggest holding. LGT Capital Partners LTD.’s holdings in Celgene were worth $42,650,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in CELG. Atlantic Trust LLC purchased a new stake in shares of Celgene during the 2nd quarter valued at about $101,000. Csenge Advisory Group purchased a new stake in shares of Celgene during the 3rd quarter valued at about $90,000. Global Trust Asset Management LLC boosted its holdings in shares of Celgene by 217.9% during the 4th quarter. Global Trust Asset Management LLC now owns 1,459 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 1,000 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of Celgene during the 3rd quarter valued at about $132,000. Finally, City Holding Co. bought a new position in shares of Celgene in the 2nd quarter worth approximately $143,000. 72.80% of the stock is currently owned by institutional investors.
NASDAQ CELG traded down $0.01 on Monday, reaching $87.39. 37,694 shares of the stock were exchanged, compared to its average volume of 24,947,664. Celgene Co. has a one year low of $58.59 and a one year high of $107.29. The stock has a market cap of $61.19 billion, a price-to-earnings ratio of 12.77, a PEG ratio of 0.46 and a beta of 1.44. The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 4.06.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.02 by $0.27. Celgene had a net margin of 19.64% and a return on equity of 108.76%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.83 billion. Sell-side analysts forecast that Celgene Co. will post 7.45 EPS for the current year.
CELG has been the topic of several recent research reports. Zacks Investment Research cut shares of Celgene from a “buy” rating to a “hold” rating in a research note on Wednesday, September 26th. Cantor Fitzgerald initiated coverage on shares of Celgene in a research note on Monday, October 1st. They issued an “overweight” rating and a $100.00 price objective on the stock. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a research note on Thursday, October 11th. BidaskClub cut shares of Celgene from a “hold” rating to a “sell” rating in a research note on Wednesday, October 24th. Finally, Leerink Swann set a $112.00 price objective on shares of Celgene and gave the stock a “hold” rating in a research note on Friday, October 26th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Celgene presently has an average rating of “Buy” and a consensus target price of $110.17.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Macon Daily and is owned by of Macon Daily. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://macondaily.com/2019/01/14/lgt-capital-partners-ltd-increases-position-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.